IP Verse

Vertex Pharmaceuticals Incorporated patent opposition analysis

Latest patents of Vertex Pharmaceuticals Incorporated opposed by its competitors

Explore Vertex Pharmaceuticals Incorporated's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 24, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4069691Sep 18, 2024Substituted Tetrahydrofurans As Modulators Of Sodium Channels1
EP2464337Jun 26, 2024Pharmaceutical Composition And Administrations Thereof1
EP2914248Oct 18, 2023Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases1
EP3925607Jun 28, 2023Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1
EP3880197Feb 22, 2023Methods Of Treatment For Cystic Fibrosis2
EP3752510Dec 7, 2022Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them1
EP3798214Sep 14, 2022Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3345625Dec 9, 2020Pharmaceutical Composition And Administrations Thereof3
EP3203840Aug 5, 2020Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3131582May 23, 2018Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1

Top competitors of Vertex Pharmaceuticals Incorporated